Search Results - "Montalban, X"

Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis by Hauser, Stephen L, Bar-Or, Amit, Comi, Giancarlo, Giovannoni, Gavin, Hartung, Hans-Peter, Hemmer, Bernhard, Lublin, Fred, Montalban, Xavier, Rammohan, Kottil W, Selmaj, Krzysztof, Traboulsee, Anthony, Wolinsky, Jerry S, Arnold, Douglas L, Klingelschmitt, Gaelle, Masterman, Donna, Fontoura, Paulo, Belachew, Shibeshih, Chin, Peter, Mairon, Nicole, Garren, Hideki, Kappos, Ludwig

“…In two trials involving patients with relapsing multiple sclerosis, the anti-CD20+ monoclonal antibody ocrelizumab was associated with lower annualized relapse…”
Get full text

Value of 3T Susceptibility-Weighted Imaging in the Diagnosis of Multiple Sclerosis by Clarke, M A, Pareto, D, Pessini-Ferreira, L, Arrambide, G, Alberich, M, Crescenzo, F, Cappelle, S, Tintoré, M, Sastre-Garriga, J, Auger, C, Montalban, X, Evangelou, N, Rovira, À

“…Previous studies have suggested that the central vein sign and iron rims are specific features of MS lesions. Using 3T SWI, we aimed to compare the frequency…”
Get full text

ECTRIMS/EAN guideline on the pharmacological treatment of people with multiple sclerosis by Montalban, X., Gold, R., Thompson, A. J., Otero‐Romero, S., Amato, M. P., Chandraratna, D., Clanet, M., Comi, G., Derfuss, T., Fazekas, F., Hartung, H. P., Havrdova, E., Hemmer, B., Kappos, L., Liblau, R., Lubetzki, C., Marcus, E., Miller, D. H., Olsson, T., Pilling, S., Selmaj, K., Siva, A., Sorensen, P. S., Sormani, M. P., Thalheim, C., Wiendl, H., Zipp, F.

“…Background and purpose Multiple sclerosis (MS) is a complex disease with new drugs becoming available in the past years. There is therefore a need for a…”
Get full text

EFNS guidelines on diagnosis and management of neuromyelitis optica by Sellner, J., Boggild, M., Clanet, M., Hintzen, R. Q., Illes, Z., Montalban, X., Du Pasquier, R. A., Polman, C. H., Sorensen, P. S., Hemmer, B.

“…Background and purpose:  Neuromyelitis optica (NMO) or Devic′s disease is a rare inflammatory and demyelinating autoimmune disorder of the central nervous…”
Get full text

Placebo-Controlled Trial of Oral Laquinimod for Multiple Sclerosis by Comi, Giancarlo, Jeffery, Douglas, Kappos, Ludwig, Montalban, Xavier, Boyko, Alexey, Rocca, Maria A, Filippi, Massimo

“…In this placebo-controlled, phase 3 trial involving patients with relapsing–remitting multiple sclerosis, oral laquinimod administered once daily reduced the…”
Get full text

The Central Vein Sign in Radiologically Isolated Syndrome by Suthiphosuwan, S, Sati, P, Guenette, M, Montalban, X, Reich, D S, Bharatha, A, Oh, J

“…Radiologically isolated syndrome describes asymptomatic individuals with incidental radiologic abnormalities suggestive of multiple sclerosis. Recent studies…”
Get full text

Assessing brain atrophy rates in a large population of untreated multiple sclerosis subtypes by DE STEFANO, N, GIORGIO, A, DINACCI, D, TEDESCHI, G, GASS, A, MONTALBAN, X, ROVIRA, A, THOMPSON, A, COMI, G, MILLER, D. H, FILIPPI, M, BATTAGLINI, M, ROVARIS, M, SORMANI, M. P, BARKHOF, F, KORTEWEG, T, ENZINGER, C, FAZEKAS, F, CALABRESE, M

“…To assess the time course of brain atrophy and the difference across clinical subtypes in multiple sclerosis (MS). The percent brain volume change (PBVC) was…”
Get full text

Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial by Comi, G, Prof, Martinelli, V, MD, Rodegher, M, MD, Moiola, L, MD, Bajenaru, O, Prof, Carra, A, Prof, Elovaara, I, Prof, Fazekas, F, Prof, Hartung, HP, Prof, Hillert, J, Prof, King, J, MD, Komoly, S, Prof, Lubetzki, C, Prof, Montalban, X, Prof, Myhr, KM, Prof, Ravnborg, M, MD, Rieckmann, P, Prof, Wynn, D, MD, Young, C, Prof, Filippi, M, MD

“…Summary Background Glatiramer acetate, approved for the treatment of relapsing-remitting multiple sclerosis, reduces relapses and disease activity and burden…”
Get full text

Do oligoclonal bands add information to MRI in first attacks of multiple sclerosis? by TINTORE, M, ROVIRA, A, MONTALBAN, X, RIO, J, TUR, C, PELAYO, R, NOS, C, TELLEZ, N, PERKAL, H, COMABELLA, M, SASTRE-GARRIGA, J

“…To evaluate whether oligoclonal bands (OB) add information to MRI in predicting both a second attack and development of disability in patients with clinically…”
Get full text

Scoring treatment response in patients with relapsing multiple sclerosis by Sormani, MP, Rio, J, Tintorè, M, Signori, A, Li, D, Cornelisse, P, Stubinski, B, Stromillo, ML, Montalban, X, De Stefano, N

“…Background: We employed clinical and magnetic resonance imaging (MRI) measures in combination, to assess patient responses to interferon in multiple sclerosis…”
Get full text

Ratio of T1-Weighted to T2-Weighted Signal Intensity as a Measure of Tissue Integrity: Comparison with Magnetization Transfer Ratio in Patients with Multiple Sclerosis by Pareto, D, Garcia-Vidal, A, Alberich, M, Auger, C, Montalban, X, Tintoré, M, Sastre-Garriga, J, Rovira, À

“…The study aim was to compare the ratio of T1WI to T2WI signal intensity (T1/T2) with magnetization transfer ratio, a marker of myelin integrity, in patients…”
Get full text

Differential diagnosis of suspected multiple sclerosis: a consensus approach by Miller, DH, Weinshenker, BG, Filippi, M, Banwell, BL, Cohen, JA, Freedman, MS, Galetta, SL, Hutchinson, M, Johnson, RT, Kappos, L, Kira, J, Lublin, FD, McFarland, HF, Montalban, X, Panitch, H, Richert, JR, Reingold, SC, Polman, CH

“…Background and objectives Diagnosis of multiple sclerosis (MS) requires exclusion of diseases that could better explain the clinical and paraclinical findings…”
Get full text

A randomized, double-blind, placebo-controlled, parallel-group, enriched-design study of nabiximols (Sativex®), as add-on therapy, in subjects with refractory spasticity caused by multiple sclerosis by Novotna, A., Mares, J., Ratcliffe, S., Novakova, I., Vachova, M., Zapletalova, O., Gasperini, C., Pozzilli, C., Cefaro, L., Comi, G., Rossi, P., Ambler, Z., Stelmasiak, Z., Erdmann, A., Montalban, X., Klimek, A., Davies, P.

“…Background:  Spasticity is a disabling complication of multiple sclerosis, affecting many patients with the condition. We report the first Phase 3…”
Get full text

Validation of a New Semiautomated Segmentation Pipeline Based on the Spinal Cord Toolbox DeepSeg Algorithm to Estimate the Cervical Canal Area by Mongay-Ochoa, N, Pareto, D, Alberich, M, Tintore, M, Montalban, X, Rovira, À, Sastre-Garriga, J

“…As in the brain reserve concept, a larger cervical canal area may also protect against disability. In this context, a semiautomated pipeline has been developed…”
Get full text

Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes by KAPPOS, L, POLMAN, C. H, POHL, C, SANDBRINK, R, FREEDMAN, M. S, EDAN, G, HARTUNG, H. P, MILLER, D. H, MONTALBAN, X, BARKHOF, F, BAUER, L, JAKOBS, P

“…To assess efficacy, safety, and tolerability of every-other-day interferon beta-1b treatment in patients with a first clinical event suggestive of multiple…”
Get full text

Oral fingolimod (FTY720) in multiple sclerosis : Two-year results of a phase II extension study by O'CONNOR, P, COMI, G, MONTALBAN, X, ANTEL, J, RADUE, E. W, DE VERA, A, POHLMANN, H, KAPPOS, L

“…To report the results of a 24-month extension of a phase II trial assessing the efficacy, safety, and tolerability of the once-daily oral…”
Get full text

Optical coherence tomography measures correlate with brain and spinal cord atrophy and multiple sclerosis disease‐related disability by Vidal‐Jordana, A., Pareto, D., Cabello, S., Alberich, M., Rio, J., Tintore, M., Auger, C., Montalban, X., Rovira, A., Sastre‐Garriga, J.

“…Background and purpose Both optical coherence tomography (OCT) and magnetic resonance imaging (MRI) volumetric measures have been postulated as potential…”
Get full text

MRI criteria for MS in patients with clinically isolated syndromes by MONTALBAN, X, TINTORE, M, ROVARIS, M, DE STEFANO, N, THOMPSON, A, YOUSRY, T, ROVIRA, A, MILLER, D. H, SWANTON, J, BARKHOF, F, FAZEKAS, F, FILIPPI, M, FREDERIKSEN, J, KAPPOS, L, PALACE, J, POLMAN, C

“…In recent years, criteria for the diagnosis of multiple sclerosis (MS) have changed, mainly due to the incorporation of new MRI criteria. While the new…”
Get full text

Baseline MRI predicts future attacks and disability in clinically isolated syndromes by TINTORE, M, ROVIRA, A, RIO, J, NOS, C, GRIVE, E, TELLEZ, N, PELAYO, R, COMABELLA, M, SASTRE-GARRIGA, J, MONTALBAN, X

“…To determine the relation between baseline MRI and both conversion to multiple sclerosis (MS) and development of disability in a cohort of patients with…”
Get full text

Phase II study of oral fingolimod (FTY720) in multiple sclerosis: 3-year results by Comi, G., O'Connor, P., Montalban, X., Antel, J., Radue, E-W., Karlsson, G., Pohlmann, H., Aradhye, S., Kappos, L.

“…In a 6-month, placebo-controlled trial, oral fingolimod (FTY720) 1.25 or 5.0 mg, once daily, significantly reduced MRI inflammatory activity and annualized…”
Get full text